Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clofibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 7/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 5/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofibrate SCHEMBL2356 | 0.98 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL3953607 | 0.98 | PPARA (1.00) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL29262880 | 0.97 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL5605019 | 0.97 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11187010 | 0.97 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11184809 | 0.97 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11180679 | 0.97 | PPARA (0.97) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL11175123 | 0.95 | PPARA (0.94) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| Clofibrate SCHEMBL28086141 | 0.95 | PPARA (0.94) | PPARACYP1A2CYP3A4ABCB11TSHR | |
| SCHEMBL21992458 | 0.94 | PPARA (0.91) | PPARACYP1A2CYP3A4ABCB11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250009744-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-01-09 | — | — | US | claimed |
| WO-2024187239-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117979991-A | Methods for treating, ameliorating or preventing infections using drug and vaccination combination therapy | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2024-05-03 | — | — | CN | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | claimed |
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| EP-4322939-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-02-21 | — | — | EP | claimed |
| CN-116963744-A | Pharmaceutical, therapeutic combination and method for preventing viral and microbial infections and their sequelae | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2023-10-27 | — | — | CN | claimed |
| EP-4262813-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | Topelia Aust Limited (ACN 652 771 670) (AU) | 2023-10-25 | — | — | EP | claimed |
| WO-2009005729-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2008153793-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008137139-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-11-13 | — | — | WO | claimed |
| US-7429568-B2 | Antidiabetic agents; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; hyperglycemia, obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-09-30 | — | — | US | claimed |
| US-7393838-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-01 | — | — | US | claimed |
| CN-1238055-C | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2006-01-25 | — | — | CN | claimed |
| CN-1443575-A | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2003-09-24 | — | — | CN | claimed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | PPARA 915/4885CYP1A2 3080/4885CYP3A4 828/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | PPARA 1110/4885CYP1A2 1173/4885CYP3A4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.